{"id":"glecaprevir-pibrentasvir-oral-tablet-mavyret","safety":{"commonSideEffects":[{"rate":"14-18%","effect":"Headache"},{"rate":"11-14%","effect":"Fatigue"},{"rate":"7-10%","effect":"Diarrhea"},{"rate":"5-8%","effect":"Nausea"},{"rate":"5-7%","effect":"Asthenia"}]},"_chembl":{"chemblId":"CHEMBL3545363","moleculeType":"Small molecule","molecularWeight":"838.88"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Glecaprevir is a pangenotypic NS3/4A protease inhibitor that prevents HCV polyprotein processing, while pibrentasvir is an NS5A inhibitor that disrupts viral RNA replication and assembly. Together, they provide potent inhibition of HCV across all major genotypes with a high barrier to resistance.","oneSentence":"Glecaprevir and pibrentasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, blocking viral replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:36.062Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus (HCV) infection, all genotypes, treatment-naïve and treatment-experienced patients"},{"name":"HCV infection in patients with compensated cirrhosis"}]},"trialDetails":[],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]","genericName":"Glecaprevir / Pibrentasvir Oral Tablet [Mavyret]","companyName":"Massachusetts General Hospital","companyId":"massachusetts-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Glecaprevir and pibrentasvir are direct-acting antivirals that inhibit hepatitis C virus (HCV) NS3/4A protease and NS5A protein, respectively, blocking viral replication. Used for Chronic hepatitis C virus (HCV) infection, all genotypes, treatment-naïve and treatment-experienced patients, HCV infection in patients with compensated cirrhosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":false,"score":3}}